A Phase 2 interventional study of Basmisanil and Placebo in Schizophrenia, sponsored by Hoffmann-La Roche. Completed at 37 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-02-09.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.
Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 10th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2016, is one of 5 in phase 2, and was the 16th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2016.
This study's enrollment of 214 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 294 across the 16 interventional studies, 1,431 across the 3 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Schizophrenia by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received matching Placebo to Basmisanil orally twice daily for 24 weeks.
Drug: Placebo
Participants received Basmisanil 80 mg orally twice daily (BID) for 24 weeks.
Drug: Basmisanil
Participants received Basmisanil 240 mg orally twice daily (BID) for 24 weeks.
Drug: Basmisanil
Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.
Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
Change From Baseline to Week 24 in MATRICS Consensus Cognitive Battery (MCCB) Neurocognitive Composite Score
The MCCB is a cognitive battery to assess 7 domains recommended by the MATRICS initiative (i.e., working memory, verbal learning, speed of processing, attention/vigilance, visual learning, social cognition, reasoning and problem solving). The MCCB neurocognitive composite T-score is a standardized mean of the six domain scores (excluding social cognition). Raw scores are converted to age and sex adjusted t-scores which are standardized to normative data, and have a mean of 50 and standard deviation of 10 in the general healthy population. A higher composite T-score represents lower impairment.
Time frame: Baseline up to Week 24
Change From Baseline to Week 24 in MCCB Cognitive Domain Scores
The MCCB is a cognitive battery to assess 7 domains recommended by the MATRICS initiative (i.e., working memory, verbal learning, speed of processing, attention/vigilance, visual learning, social cognition, reasoning and problem solving). Raw scores are converted to age and sex adjusted t-scores which are standardized to normative data, and have a mean of 50 and standard deviation of 10 in the general healthy population. A higher T-score represents lower impairment.
Time frame: Baseline up to Week 24
Change From Baseline to Week 24 in Wechsler Memory Scale Fourth Edition, Verbal Paired Associates (WMS IV-PAL) Score
The Paired Associates Learning (PAL I and II) of the WMS-IV (Wechsler Memory Scale Fourth edition) is a test of verbal learning and memory that requires the participant to learn novel word pairs. The participant learns the word pairs across learning trials and is asked to recall them immediately (PAL I) or after a 30-minute delay (PAL II). Data is presented here for 3 Scores: VPA I total raw score, VPA II total raw score and VPA II Recognition total raw score. The total raw score ranges for these 3 Scores are 0 to 56, 0 to 14 and 0 to 40 respectively, with larger total raw scores indicating better performance.
Time frame: Baseline up to Week 24
Change From Baseline to Week 24 in Wechsler Memory Scale Fourth Edition, Logical Memory Test (WMS IV-LM) Score
Logical memory (LM) assesses narrative memory under free-recall conditions. Two short stories are presented orally. The examinee is asked to retell each story from memory immediately after hearing it (LM I). In the delayed condition (LM II), the examinee is asked to retell both stories from the immediate condition (delayed free recall). Data is presented here for 2 Scores: LM I total raw score and LM II total raw score. The total raw score range is from 0 to 50 with larger total raw scores indicating better performance.
Time frame: Baseline up to Week 24
Change From Baseline to Week 24 in Ratio Between Trail Making Test (TMT)- Part B and TMT- Part A Scores
The TMT consists of two parts: Trail Making Part A, which is a part of the standard MCCB and Trail Making Part B additionally included in this study. Circles containing numbers (Part A) or both numbers and letters (Part B) must be sequentially connected. The difference (ratio) in performance between Part A and Part B reflects executive processes and will be used to assess executive functioning including cognitive set shifting abilities and data for this ratio is presented here. Smaller ratio values, hence decreases from baseline (TMT-B/TMT-A ratio values below 1) indicate higher executive functioning capabilities.
Time frame: Baseline up to Week 24
Change From Baseline to Week 24 in Personal and Social Performance (PSP) Total Score
The PSP Total Score is an integer result in the range of 0 to 100. Larger values, hence increases from baseline in the PSP total score, indicate higher social and personal functioning.
Time frame: Baseline up to Week 24
Change From Baseline to Week 24 in Schizophrenia Cognition Rating Scale (SCoRS) Total Score
The main parameter of interest for the Schizophrenia Cognition Rating Scale (SCoRS) is the SCoRS 'Total Score'. The total score range is from 0 to 80 with lower scores indicating better day-to-day functioning.
Time frame: Baseline up to Week 24
Change From Baseline to Week 24 in Clinical Global Impression Severity (CGI-S) Rating
Values for the CGI-S Scale are encoded by the numerical values from 1 to 7 respectively. Higher numerical values represent greater impairment.
Time frame: Baseline up to Week 24
Change From Baseline to Week 24 in Clinical Global Impression Improvement (CGI-I) Rating
Values for the CGI-I Scale are encoded by the numerical values from 1 to 7 respectively. Higher numerical values represent greater impairment.
Time frame: Baseline up to Week 24
Change From Baseline to Week 24 in Schizophrenia Quality of Life Scale (SQLS)
The SQLS is a patient reported scale consisting of 33 items: 2 domain scores (Cognition \& Vitality Score \[SQLS-CV\] and Psycho-social Score \[SQLS-P\]) as well as a Total score (SQLS-T) are derived. The overall score range is from 0 to 100. On all scales, higher scores represent a lower quality of life.
Time frame: Baseline up to Week 24
Percentage of Participants With Adverse Events (AEs)
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.
Time frame: Baseline up to 4 weeks after the last dose of study drug (up to 28 weeks)
Apparent Clearance of Basmisanil at Steady State (CL/F,ss)
Population PK model estimated apparent oral clearance of Basmisanil at steady-state.
Time frame: Pre-dose (hour 0) in Days 7, 14, 42, 84, 168
Apparent Volume of Distribution of Basmisanil at Steady State (Vz/F,ss)
Population PK model estimated apparent volume of distribution of Basmisanil at steady-state.
Time frame: Pre-dose (hour 0) in Days 7, 14, 42, 84, 168
Area Under the Curve of Basmisanil at Steady State (AUC,ss)
Population PK model estimated AUC of Basmisanil at steady-state.
Time frame: Pre-dose (hour 0) in Days 7, 14, 42, 84, 168
Maximum Plasma Concentration of Basmisanil at Steady State (Cmax,ss)
Population PK model estimated maximum plasma concentration of Basmisanil at steady-state (ss).
Time frame: Pre-dose (hour 0) in Days 7, 14, 42, 84, 168
The study was conducted at 37 centers in 1 country.
| Milestone | Placebo | Basmisanil 80mg BID | Basmisanil 240mg BID |
|---|---|---|---|
| Started | 81 | 54 | 78 |
| Completed | 61 | 40 | 62 |
| Not completed | 20 | 14 | 16 |
| Withdrew: Adverse event | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 8 | 4 | 3 |
| Withdrew: Non-compliance with study drug | 0 | 2 | 1 |
| Withdrew: Multiple reasons | 1 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 8 | 10 |
| Withdrew: Completed or discontinued information is missing | 1 | 0 | 0 |
The MCCB is a cognitive battery to assess 7 domains recommended by the MATRICS initiative (i.e., working memory, verbal learning, speed of processing, attention/vigilance, visual learning, social cognition, reasoning and problem solving). The MCCB neurocognitive composite T-score is a standardized mean of the six domain scores (excluding social cognition). Raw scores are converted to age and sex adjusted t-scores which are standardized to normative data, and have a mean of 50 and standard deviation of 10 in the general healthy population. A higher composite T-score represents lower impairment.
| Composite T-Score | Placebo | Basmisanil 240mg BID |
|---|---|---|
| Baseline | 32.50 ± 14.47 | 32.36 ± 11.44 |
| Week 12 Day 84 | -0.17 ± 5.07 | -0.28 ± 6.08 |
| Week 24 Day 168 | 1.08 ± 5.78 | 1.36 ± 4.80 |
The MCCB is a cognitive battery to assess 7 domains recommended by the MATRICS initiative (i.e., working memory, verbal learning, speed of processing, attention/vigilance, visual learning, social cognition, reasoning and problem solving). Raw scores are converted to age and sex adjusted t-scores which are standardized to normative data, and have a mean of 50 and standard deviation of 10 in the general healthy population. A higher T-score represents lower impairment.
| T-score | Placebo | Basmisanil 240mg BID |
|---|---|---|
| Baseline (Attention/Vigilance) | 40.75 ± 12.31 | 39.66 ± 12.08 |
| Week 12 Day 84 (Attention/Vigilance) | -0.16 ± 8.00 | -0.14 ± 8.80 |
| Week 24 Day 168 (Attention/Vigilance) | 0.63 ± 6.89 | 0.51 ± 8.49 |
| Baseline (Reasoning and Problem Solving) | 42.75 ± 12.61 | 43.71 ± 10.12 |
| Week 12 Day 84 (Reasoning and Problem Solving) | 0.05 ± 8.94 | 0.05 ± 6.07 |
| Week 24 Day 168 (Reasoning and Problem Solving) | 1.69 ± 7.23 | 2.18 ± 6.13 |
| Baseline (Social Cognition) | 37.79 ± 13.30 | 38.38 ± 13.09 |
| Week 12 Day 84 (Social Cognition) | 0.62 ± 7.74 | -0.62 ± 8.55 |
| Week 24 Day 168 (Social Cognition) | -1.71 ± 7.24 | 0.96 ± 7.10 |
| Baseline (Speed of Processing) | 37.08 ± 13.10 | 37.81 ± 12.70 |
| Week 12 Day 84 (Speed of Processing) | -1.48 ± 7.41 | -1.66 ± 6.07 |
| Week 24 Day 168 (Speed of Processing) | 0.37 ± 6.85 | 0.13 ± 4.88 |
| Baseline (Verbal Learning) | 37.34 ± 9.20 | 36.53 ± 7.41 |
| Week 12 Day 84 (Verbal Learning) | 0.26 ± 7.99 | 0.45 ± 7.01 |
| Week 24 Day 168 (Verbal Learning) | 0.46 ± 8.33 | 0.36 ± 6.53 |
| Baseline (Visual Learning) | 35.96 ± 12.18 | 35.38 ± 11.98 |
| Week 12 Day 84 (Visual Learning) | -0.91 ± 8.14 | -0.48 ± 9.35 |
| Week 24 Day 168 (Visual Learning) | -0.98 ± 8.56 | 0.53 ± 9.33 |
| Baseline (Working Memory) | 35.99 ± 12.56 | 36.23 ± 10.09 |
| Week 12 Day 84 (Working Memory) | 1.62 ± 6.99 | 0.76 ± 6.41 |
| Week 24 Day 168 (Working Memory) | 2.37 ± 6.34 | 1.76 ± 6.68 |
The Paired Associates Learning (PAL I and II) of the WMS-IV (Wechsler Memory Scale Fourth edition) is a test of verbal learning and memory that requires the participant to learn novel word pairs. The participant learns the word pairs across learning trials and is asked to recall them immediately (PAL I) or after a 30-minute delay (PAL II). Data is presented here for 3 Scores: VPA I total raw score, VPA II total raw score and VPA II Recognition total raw score. The total raw score ranges for these 3 Scores are 0 to 56, 0 to 14 and 0 to 40 respectively, with larger total raw scores indicating better performance.
| Scores on a Scale | Placebo | Basmisanil 240mg BID |
|---|---|---|
| Baseline (VPA I total raw score) | 31.14 ± 12.53 | 32.30 ± 11.75 |
| Week 12 Day 84 (VPA I total raw score) | 2.14 ± 6.55 | 0.36 ± 7.33 |
| Week 24 Day 168 (VPA I total raw score) | 4.42 ± 6.58 | 5.09 ± 6.40 |
| Baseline (VPA II total raw score) | 9.25 ± 3.76 | 9.77 ± 3.54 |
| Week 12 Day 84 (VPA II total raw score) | 0.12 ± 2.29 | 0.26 ± 2.15 |
| Week 24 Day 168 (VPA II total raw score) | 0.69 ± 2.16 | 1.60 ± 2.33 |
| Baseline (VPA II recognition total raw score) | 36.24 ± 5.37 | 37.36 ± 5.12 |
| Week 12 Day 84 (VPA II recognition total raw score) | 0.48 ± 5.43 | -0.55 ± 2.92 |
| Week 24 Day 168 (VPA II recognition total raw score) | 1.12 ± 5.60 | 0.36 ± 2.80 |
Logical memory (LM) assesses narrative memory under free-recall conditions. Two short stories are presented orally. The examinee is asked to retell each story from memory immediately after hearing it (LM I). In the delayed condition (LM II), the examinee is asked to retell both stories from the immediate condition (delayed free recall). Data is presented here for 2 Scores: LM I total raw score and LM II total raw score. The total raw score range is from 0 to 50 with larger total raw scores indicating better performance.
| Scores on a Scale | Placebo | Basmisanil 240mg BID |
|---|---|---|
| Baseline (LM I) | 16.55 ± 5.80 | 16.22 ± 8.13 |
| Week 12 Day 84 (LM I) | -2.60 ± 5.33 | -0.83 ± 5.66 |
| Week 24 Day 168 (LM I) | -3.02 ± 4.96 | -2.29 ± 5.29 |
| Baseline (LM II) | 13.72 ± 6.57 | 14.29 ± 8.22 |
| Week 12 Day 84 (LM II) | -2.91 ± 6.04 | -2.63 ± 6.08 |
| Week 24 Day 168 (LM II) | -2.73 ± 4.94 | -3.22 ± 5.15 |
The TMT consists of two parts: Trail Making Part A, which is a part of the standard MCCB and Trail Making Part B additionally included in this study. Circles containing numbers (Part A) or both numbers and letters (Part B) must be sequentially connected. The difference (ratio) in performance between Part A and Part B reflects executive processes and will be used to assess executive functioning including cognitive set shifting abilities and data for this ratio is presented here. Smaller ratio values, hence decreases from baseline (TMT-B/TMT-A ratio values below 1) indicate higher executive functioning capabilities.
| Ratio | Placebo | Basmisanil 240mg BID |
|---|---|---|
| Baseline | 3.27 ± 1.65 | 3.12 ± 1.58 |
| Week 12 Day 84 | -0.37 ± 1.19 | -0.12 ± 1.34 |
| Week 24 Day 168 | -0.23 ± 2.00 | -0.06 ± 1.22 |
The PSP Total Score is an integer result in the range of 0 to 100. Larger values, hence increases from baseline in the PSP total score, indicate higher social and personal functioning.
| Scores on a Scale | Placebo | Basmisanil 240mg BID |
|---|---|---|
| Baseline | 59.82 ± 11.88 | 60.88 ± 10.87 |
| Week 12 Day 84 | 3.13 ± 8.30 | 2.26 ± 8.68 |
| Week 24 Day 168 | 3.75 ± 9.66 | 4.14 ± 10.05 |
The main parameter of interest for the Schizophrenia Cognition Rating Scale (SCoRS) is the SCoRS 'Total Score'. The total score range is from 0 to 80 with lower scores indicating better day-to-day functioning.
| Scores on a Scale | Placebo | Basmisanil 240mg BID |
|---|---|---|
| Baseline | 37.07 ± 8.52 | 36.53 ± 9.84 |
| Week 12 Day 84 | -2.91 ± 6.06 | -3.66 ± 5.78 |
| Week 24 Day 168 | -3.71 ± 7.19 | -4.02 ± 7.79 |
Values for the CGI-S Scale are encoded by the numerical values from 1 to 7 respectively. Higher numerical values represent greater impairment.
| Scores on a Scale | Placebo | Basmisanil 240mg BID |
|---|---|---|
| Baseline | 2.45 ± 0.62 | 2.39 ± 0.75 |
| Week 12 Day 84 | -0.21 ± 0.67 | -0.24 ± 0.60 |
| Week 24 Day 168 | -0.19 ± 0.56 | -0.29 ± 0.76 |
Values for the CGI-I Scale are encoded by the numerical values from 1 to 7 respectively. Higher numerical values represent greater impairment.
| Scores on a Scale | Placebo | Basmisanil 240mg BID |
|---|---|---|
| Week 12 Day 84 | -0.45 ± 0.86 | -0.45 ± 0.86 |
| Week 24 Day 168 | -0.62 ± 1.01 | -0.64 ± 0.91 |
The SQLS is a patient reported scale consisting of 33 items: 2 domain scores (Cognition \& Vitality Score \[SQLS-CV\] and Psycho-social Score \[SQLS-P\]) as well as a Total score (SQLS-T) are derived. The overall score range is from 0 to 100. On all scales, higher scores represent a lower quality of life.
| Scores on a Scale | Placebo | Basmisanil 240mg BID |
|---|---|---|
| Baseline (SQLS Cognition & Vitality Score) | 33.81 ± 17.41 | 34.21 ± 18.59 |
| Week 12 Day 84 (SQLS Cognition & Vitality Score) | -2.26 ± 12.66 | 0.21 ± 14.00 |
| Week 24 Day 168 (SQLS Cognition & Vitality Score) | -0.78 ± 15.71 | -4.32 ± 13.59 |
| Baseline (SQLS Psychosocial Score) | 31.48 ± 20.26 | 30.84 ± 20.88 |
| Week 12 Day 84 (SQLS Psychosocial Score) | -0.88 ± 12.42 | 0.80 ± 14.49 |
| Week 24 Day 168 (SQLS Psychosocial Score) | -1.78 ± 12.87 | -1.58 ± 13.27 |
| Baseline (SQLS Total Score) | 32.40 ± 18.51 | 32.14 ± 19.19 |
| Week 12 Day 84 (SQLS Total Score) | -1.42 ± 11.80 | 0.57 ± 12.98 |
| Week 24 Day 168 (SQLS Total Score) | -1.38 ± 12.89 | -2.66 ± 12.31 |
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.
| Percentage of Participants | Placebo | Basmisanil 80mg BID | Basmisanil 240mg BID |
|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 39.5 | 46.3 | 48.7 |
Population PK model estimated apparent oral clearance of Basmisanil at steady-state.
No measurements were reported for this outcome.
Population PK model estimated apparent volume of distribution of Basmisanil at steady-state.
No measurements were reported for this outcome.
Population PK model estimated AUC of Basmisanil at steady-state.
| ng*mL/hr | Basmisanil 80mg BID | Basmisanil 240mg BID |
|---|---|---|
| Area Under the Curve of Basmisanil at Steady State (AUC,ss) | 41640 (31464 to 51816) | 87624 (66504 to 108768) |
Population PK model estimated maximum plasma concentration of Basmisanil at steady-state (ss).
| ng/mL | Basmisanil 80mg BID | Basmisanil 240mg BID |
|---|---|---|
| Maximum Plasma Concentration of Basmisanil at Steady State (Cmax,ss) | 2079 (1645 to 2513) | 4374 (3455 to 5294) |
Collected over Baseline up to 4 weeks after the last dose of study drug (up to 28 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/81 (0%) | 5/81 (6.2%) | 10/81 (12.3%) |
| Basmisanil 80mg BID | 0/54 (0%) | 0/54 (0%) | 10/54 (18.5%) |
| Basmisanil 240mg BID | 0/78 (0%) | 4/78 (5.1%) | 12/78 (15.4%) |
| Event | Placebo | Basmisanil 80mg BID | Basmisanil 240mg BID |
|---|---|---|---|
| Psychotic disorderPsychiatric disorders | 1/81 | 0/54 | 2/78 |
| Cholecystitis acuteHepatobiliary disorders | 0/81 | 0/54 | 1/78 |
| Diabetic complicationMetabolism and nutrition disorders | 0/81 | 0/54 | 1/78 |
| Supraventricular extrasystolesCardiac disorders | 1/81 | 0/54 | 0/78 |
| PancreatitisGastrointestinal disorders | 1/81 | 0/54 | 0/78 |
| SchizophreniaPsychiatric disorders | 1/81 | 0/54 | 0/78 |
| Suicide attemptPsychiatric disorders | 1/81 | 0/54 | 0/78 |
| Event | Placebo | Basmisanil 80mg BID | Basmisanil 240mg BID |
|---|---|---|---|
| HeadacheNervous system disorders | 1/81 | 3/54 | 7/78 |
| FatigueGeneral disorders | 6/81 | 1/54 | 1/78 |
| DiarrhoeaGastrointestinal disorders | 4/81 | 3/54 | 2/78 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/81 | 3/54 | 0/78 |
| SomnolenceNervous system disorders | 0/81 | 0/54 | 4/78 |
| Age, Continuous(Years) | Placebo | Basmisanil 80mg BID | Basmisanil 240mg BID | Total |
|---|---|---|---|---|
| Mean | 36.4 ± 8.2 | 36.8 ± 8.6 | 37.4 ± 8.4 | 36.9 ± 8.4 |
| Sex: Female, Male(Participants) | Placebo | Basmisanil 80mg BID | Basmisanil 240mg BID | Total |
|---|---|---|---|---|
| Female | 20 | 12 | 18 | 50 |
| Male | 61 | 42 | 60 | 163 |
| Race/Ethnicity, Customized(Participants) | Placebo | Basmisanil 80mg BID | Basmisanil 240mg BID | Total |
|---|---|---|---|---|
| Hispanic or Latino | 13 | 7 | 12 | 32 |
| Not Hispanic or Latino | 68 | 47 | 66 | 181 |
| Race/Ethnicity, Customized(Participants) | Placebo | Basmisanil 80mg BID | Basmisanil 240mg BID | Total |
|---|---|---|---|---|
| Asian | 3 | 0 | 2 | 5 |
| Black or African American | 51 | 30 | 51 | 132 |
| MULTIPLE | 1 | 0 | 0 | 1 |
| UNKNOWN | 1 | 1 | 2 | 4 |
| White | 25 | 23 | 23 | 71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Nov 2016 to primary completion in Dec 2019, 36 months.
Results were first posted in Feb 2021, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 36 months is above that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Basmisanil